

Friday, 08 January 2010

Dear,

**Discontinuation – NeoRecormon® (epoetin beta) presentations  
RecoPen and RecoPen cartridges (10000IU, 20000IU). Multidose vial 100,000IU**

Following a worldwide product portfolio review and low demand we wish to notify you of the discontinuation for the following presentations of NeoRecormon in the UK. The discontinuation is not for safety issues and has already been implemented in many countries. Estimated dates are indicated, but please be aware that stock may be exhausted sooner than this if demand increases.

**RecoPen range:**

10,000 IU lyophilisate and solvent for solution for injection in cartridge (Pack of 3).

PL no: EU/1/97/031/022

Estimated to be available until March 2010 (*stock is now exhausted due to unexpected high demand thus this presentation is no longer available with immediate effect*)

20,000 IU lyophilisate and solvent for solution for injection in cartridge (Pack of 3).

PL no: EU/1/97/031/024

Estimated to be available until June 2010

The RecoPen range will no longer be available when current stocks are exhausted.

The RecoPen device and needles will remain available free of charge from Roche Customer Care (Tel: 0800 731 5711) until the expiry date of the cartridges.

**Multidose vial:**

100,000 IU multidose lyophilisate and solvent for solution for injection

PL no: EU/1/97/031/020

Estimated to be available until June 2010

**Roche Products Limited**

6 Falcon Way, Shire Park  
Welwyn Garden City  
Herts AL7 1TW

Medical Information

Tel. 0800 3281629

Email [medinfo.uk@roche.com](mailto:medinfo.uk@roche.com)

Registered in England  
No. 100674

NeoRecormon is currently indicated for:

- Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients.
- Prevention of anaemia of prematurity in infants with a birth weight of 750 to 1500g and a gestational age of less than 34 weeks (pre-filled syringe only).
- Treatment of symptomatic anaemia in adult patients with non-myeloid malignancies receiving chemotherapy.
- Increasing the yield of autologous blood from patients in a pre-donation programme.

The following NeoRecormon presentations remain available for prescription:

**Multidose vial** : 50,000 IU multidose lyophilisate and solvent for solution for injection

**Prefilled syringes** : 500, 2000, 3000, 4000, 5000, 6000, 10,000, 20,000, and 30,000 IU solution for injection in pre-filled syringe. 500IU syringes are supplied with 30G needles and other strengths with 27G needles.

Smaller gauge needles (up to 31G) may be used with the pre-filled syringes for paediatric patients.

Other erythropoietins are also available and are listed in the British National Formulary (Section 9.1.3).

The NeoRecormon Summary of Product Characteristics can be found at <http://emc.medicines.org.uk/>

If you require any further information regarding this please do not hesitate to contact our Roche Medical Information team on Freephone 0800 328 1629 or by e-mail to [medinfo.uk@roche.com](mailto:medinfo.uk@roche.com)

Yours sincerely,



Dr Colin Wheeler  
Medical Manager - Metabolism, Virology,  
Anaemia and Transplant